Press Releases Johnson & Johnson Wiener Boerse

Equities

JNJ

US4781601046

Real-time Estimate Tradegate Other stock markets 01:35:34 03/07/2024 pm IST			5-day change	1st Jan Change
135.7 ^EUR	-0.77%		-1.10%	-3.46%

02/07	J&J: promising results in multiple myeloma	CF
02/07	Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

State AG Updates: June 6-13, 2024	02/07	AQ
CHMP adopts positive opinion for BALVERSA for the treatment of adult patients	01/07	AQ
Johnson & Johnson - Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class	01/07	AQ
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients	29/06	PU
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	28/06	PR
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations	28/06	PU
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	28/06	BU
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)	27/06	AQ
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	25/06	AQ
Johnson & Johnson completes acquisition of Proteologix, Inc.	24/06	AQ
Johnson & Johnson Completes Acquisition of Proteologix, Inc.	21/06	BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications	21/06	AQ
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	21/06	PR
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	20/06	BU
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction	20/06	PR
Johnson & Johnson - Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer	18/06	AQ
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products	18/06	BU
J&J commits five-year investment in Italian medicine manufacturing	17/06	AQ
Johnson & Johnson - Late-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study	17/06	AQ
Johnson & Johnson - TALVEY demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma	17/06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST